<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">Acute MI with or without COVID-19 represents a life-threatening condition that requires adjunctive medical therapies such as potent antiplatelet drugs and monitoring to anticipate complications. However, the enhanced infectious potency in humans [
 <xref ref-type="bibr" rid="CR75">75</xref>] mandates a fundamental risk assessment to carefully weigh the relative advantages against disadvantages of treating cardiovascular disease while preventing the risk of SARS-CoV-2 transmission.
</p>
